Literature DB >> 2571912

Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex.

S Matsubara1, H Y Meltzer.   

Abstract

The effect of acute treatment with seven atypical antipsychotic drugs and four typical antipsychotic drugs on serotonin2 (5-HT2) receptor binding sites in rat cerebral cortex was studied. Among the atypical antipsychotic drugs examined, clozapine, fluperlapine, RMI-81582 and setoperone decreased the density of 5-HT2 receptors, but ticspirone, amperozide and melperone did not. None of the drugs affected the Kd value. Among the typical antipsychotic drugs, loxapine decreased Bmax and increased the Kd of 5-HT2 receptor binding sites, whereas chlorpromazine and cis-flupenthixol had no effect. Clothiapine, a typical antipsychotic drug of the same chemical class as clozapine, decreased Bmax without increasing Kd. The downregulation of 5-HT2 receptor binding sites following a single injection of clozapine, 20 mg/kg, remained almost unchanged during the first 72 hrs and was still significantly decreased for up to 120 hrs. There was no relationship between the affinity for the downregulation of rat cortical 5-HT2 receptor binding site and 5-HT2 receptor density. Coadministration of the D1 dopamine agonist, SKF-38393, did not affect the clozapine-induced downregulation. It is suggested that rapid and prolonged downregulation of 5-HT2 receptor sites is characteristic of some but not all atypical antipsychotic drugs and is not specific to atypical antipsychotic drugs. Dibenzo-epines (clozapine, loxapine, amoxapine, chlothiapine) consistently downregulate 5-HT2 receptors in frontal cortex after acute treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571912     DOI: 10.1016/0024-3205(89)90027-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  13 in total

Review 1.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients.

Authors:  R C Arora; H Y Meltzer
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  Seroquel: biochemical profile of a potential atypical antipsychotic.

Authors:  C F Saller; A I Salama
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Effects of clozapine and 2,5-dimethoxy-4-methylamphetamine [DOM] on 5-HT2A receptor expression in discrete brain areas.

Authors:  M M Doat-Meyerhoefer; R Hard; J C Winter; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  2005-08       Impact factor: 3.533

5.  Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.

Authors:  Amarendra N Singh; Cia Barlas; Huma Saeedi; Ram K Mishra
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

Review 6.  Clozapine: new research on efficacy and mechanism of action.

Authors:  H Y Meltzer; B Bastani; L Ramirez; S Matsubara
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

7.  Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.

Authors:  H Y Meltzer; M A Lee; R Ranjan; E A Mason; P A Cola
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

8.  A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes.

Authors:  A N Singh; C Barlas; S Singh; P Franks; R K Mishra
Journal:  J Psychiatry Neurosci       Date:  1996-01       Impact factor: 6.186

Review 9.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of Akt.

Authors:  Cullen L Schmid; John M Streicher; Herbert Y Meltzer; Laura M Bohn
Journal:  Neuropsychopharmacology       Date:  2014-02-17       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.